Ascendis Pharma A/S (NASDAQ:ASND – Get Free Report) and Viridian Therapeutics (NASDAQ:VRDN – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, institutional ownership, risk and valuation.
Risk and Volatility
Ascendis Pharma A/S has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. Comparatively, Viridian Therapeutics has a beta of 1.07, indicating that its stock price is 7% more volatile than the S&P 500.
Valuation and Earnings
This table compares Ascendis Pharma A/S and Viridian Therapeutics”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Ascendis Pharma A/S | $814.57 million | 19.86 | -$258.00 million | $12.89 | 20.11 |
| Viridian Therapeutics | $26.31 million | 134.88 | -$342.60 million | ($3.84) | -8.14 |
Ascendis Pharma A/S has higher revenue and earnings than Viridian Therapeutics. Viridian Therapeutics is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.
Analyst Ratings
This is a summary of recent recommendations for Ascendis Pharma A/S and Viridian Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Ascendis Pharma A/S | 0 | 2 | 19 | 0 | 2.90 |
| Viridian Therapeutics | 1 | 0 | 11 | 0 | 2.83 |
Ascendis Pharma A/S currently has a consensus target price of $305.95, suggesting a potential upside of 18.00%. Viridian Therapeutics has a consensus target price of $41.00, suggesting a potential upside of 31.20%. Given Viridian Therapeutics’ higher possible upside, analysts plainly believe Viridian Therapeutics is more favorable than Ascendis Pharma A/S.
Profitability
This table compares Ascendis Pharma A/S and Viridian Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Ascendis Pharma A/S | 70.99% | 32.54% | 7.71% |
| Viridian Therapeutics | -1,620.79% | -79.67% | -44.72% |
Summary
Ascendis Pharma A/S beats Viridian Therapeutics on 9 of the 12 factors compared between the two stocks.
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company headquartered in Denmark that develops medicines for rare diseases, with a focus on endocrinology. Founded in 2006, the company uses its TransCon technology platform to design therapies intended to provide sustained delivery of medicines. Its commercial products include SKYTROFA (lonapegsomatropin), a once-weekly growth hormone treatment for children with growth hormone deficiency, and YORVIPATH (palopegteriparatide), a treatment for adults with hypoparathyroidism.
About Viridian Therapeutics
Viridian Therapeutics is a clinical-stage biopharmaceutical company developing medicines for serious diseases, with a primary focus on thyroid eye disease (TED), an autoimmune condition that can cause inflammation and changes around the eyes. The company’s pipeline includes veligrotug, an investigational antibody that targets the insulin-like growth factor 1 receptor, a pathway involved in TED. Viridian is also developing additional antibody-based candidates intended to offer treatment options, including formulations designed for under-the-skin administration.
Receive News & Ratings for Ascendis Pharma A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ascendis Pharma A/S and related companies with MarketBeat.com's FREE daily email newsletter.
